Cost-Effectiveness of Left Ventricular Assist Device for Transplant-Ineligible Patients
JAMA Network Open · 2025
DOI: 10.1001/jamanetworkopen.2025.4483 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, 2025. Verfasst von Elisabeth M Schaffer und 3 weiteren Autor:innen. Beteiligte Einrichtung: Saw Swee Hock School of Public Health, National University of Singapore, Singapore. Hauptthemen laut MEDLINE: Heart-Assist Devices, Cost-Benefit Analysis, Heart Failure. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Singapore is considering subsidizing left ventricular assist devices (LVADs) for end-stage heart failure (ESHF) and uses cost-effectiveness evidence to inform the determination. Yet, no economic evaluation has thus far been conducted.
Objective
To estimate the lifetime cost-effectiveness of LVAD compared with optimal medical management for transplant-ineligible patients. Design, Setting, and Participants This economic evaluation used a Markov model to simulate survival, stroke incidence, other adverse events, and heart failure hospitalizations for a cohort of adult patients in Singapore with transplant-ineligible ESHF, most of whom were inotrope dependent. Latest LVAD mortality data from a randomized clinical trial were age-adjusted, and an indirect comparison of prior trial results was performed to estimate survival for inotrope-dependent and inotrope-independent patients. Costs were estimated (in 2023 Singapore dollars [SGD]) using cohort billing data from 2017 to 2022 and National Heart Centre Singapore LVAD charges. Statistical analysis was performed from December 2023 to July 2024. Exposure HeartMate 3 LVAD (Abbott). Main Outcomes and Measures Health care costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio (ICER) evaluated against a threshold of SGD 114 000 (US $85 075) per QALY gained.
Results
At model initiation, the cohort had a mean (SD) age of 64 (12) years, and 78% (range, 68%-86%) of patients were inotrope dependent. In the base case analysis, LVAD yielded an additional 3.45 QALYs at an incremental cost of SGD 404 678 (US $301 999), producing an ICER of SGD 117 370 (US $87 590) per QALY gained for the transplant-ineligible population. The ICER differed for inotrope-use subgroups at SGD 106 458 (US $79 446) per QALY gained for inotrope-dependent patients and SGD 174 798 (US $130 446) per QALY gained for inotrope-independent patients (with 59% and 19% probabilities, respectively, of attaining high value). The inotrope-dependent ICER was sensitive to model input changes and structural assumptions, whereas the inotrope-independent ICER consistently exceeded the high-value threshold in scenario analyses. In threshold analyses, a 44% reduction in the total implantation price or a 54% reduction in the all-cause mortality hazard were required for LVAD to be high value for inotrope-independent patients. Confidence that the inotrope-dependent ICER is high value increased to 75% and 85% with respective 20% and 33% reductions in total implantation price. Conclusions and Relevance In this economic evaluation comparing LVAD with optimal medical management, LVAD was potentially high value for most transplant-ineligible patients who are inotrope dependent. Confidence in this result was improved with plausible price reductions, yet only extreme changes rendered LVAD high value for inotrope-independent patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Saw Swee Hock School of Public Health, National University of Singapore, Singapore.
- Health Services and Systems Research, Duke-NUS Medical School, Singapore.
Zitieren
APA
Schaffer, E. M., Su, R. G. S., Chay, J., & Finkelstein, E. A. (2025). Cost-Effectiveness of Left Ventricular Assist Device for Transplant-Ineligible Patients. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2025.4483
Vancouver
Schaffer EM, Su RGS, Chay J, Finkelstein EA. Cost-Effectiveness of Left Ventricular Assist Device for Transplant-Ineligible Patients. JAMA Network Open. 2025. doi:10.1001/jamanetworkopen.2025.4483
BibTeX
@article{Schaffer2025,
author = {Schaffer, Elisabeth M and Su, Rebecca Giok Sim and Chay, Junxing and Finkelstein, Eric A},
title = {Cost-Effectiveness of Left Ventricular Assist Device for Transplant-Ineligible Patients},
journal = {JAMA Network Open},
year = {2025},
doi = {10.1001/jamanetworkopen.2025.4483}
}
EUVIMED